BASIC FACTS
DATE OF LAUNCH
15 FEBRUARY 2019
CATEGORY
EQUITY
TYPE
SMALL CAP
AUM*
Rs.5,482 Crore
BENCHMARK
NIFTY SMALLCAP 250
TOTAL RETURN INDEX
WHAT IT COSTS
NAV**
GROWTH OPTION
Rs.25.58
IDCW
Rs.23.76
MINIMUM INVESTMENT
Rs.5,000
MINIMUM SIP AMOUNT
Rs.1,000
EXPENSE RATIO*** (%)
1.79
EXIT LOAD
1% for redemption within 365 days
*AS ON 30 APRIL 2023
**AS ON 30 MAY 2023
***AS ON 30 APRIL 2023
FUND MANAGERS
AJAY KHANDELWAL / SHRIDATTA BHANDWALDAR
1 YEAR, 4 MONTHS /
3 YEARS, 6 MONTHS
Recent portfolio changes
New Entrants
ITC, Kaynes Technology India, Reliance Industries (Mar), Ajanta Pharma, Global Health, Rossari Biotech (Apr).
Increasing allocation
Bajaj Finance, Balrampur Chini Mills, Can Fin Homes, EID-Parry (India), JK Lakshmi Cement, Kaynes Technology India, Kei Industries (Apr)
Should you buy?
In this small cap fund, the fund managers place high emphasis on downside protection and limiting drawdowns. They run a highly diversified portfolio with modest positions even in top bets, given the risks inherent in this segment. They prefer high quality businesses backed by strong business models, competent management and good governance. The fund has been running for only a few years, but has established a strong track record in this short time span. It delivered outsized returns during the favourable years of 2020 and 2021 and contained downside much better than peers last year. However, it has seen a dip in performance since, lagging index and peers sharply. It must recover quickly to build on its strong start.
(Source: Value Research)
